Form D · Biotechnology
Tempero Bio, Inc.
Oakland, CA · CIK 0002095129
Offering snapshot reported Nov 4, 2025 · SEC filing
- Reported sold
- $77M Offering amount: $77M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 30, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 4, 2025 | Initial | $76,958,457 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-562889
Offering of Series B-1 Preferred Stock and Series B-2 Preferred Stock (collectively "Preferred Stock") and the underlying shares of Common Stock issuable upon conversion of Preferred Stock.
Source: Form D, filed Nov 4, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ricardo Dolmetsch | Director, Executive |
| Joshua Gertsman | Director |
| Francisco Gimenez | Director |
| Joseph Jimenez | Director |
| Paul Johnson | Director, Executive |
| Christian Klee | Executive |
| Julie Shah | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1111 Broadway, Suite 1300
Oakland, CA, 94607
Oakland, CA, 94607